Invitae Corp: directors' dealings · United States · SEC (Form 4)

About Invitae Corp

Invitae Corp. is a U.S.-based medical genetics and molecular diagnostics company that built its business around clinical genetic testing. Historically listed in the United States on the NYSE under the ticker NVTA, the company developed a platform aimed at making genetic information more accessible and actionable for physicians, hospitals, laboratories, and patients. Invitae was founded in 2010 and established its headquarters in San Francisco, California, placing it in one of the most active biotech hubs in the United States. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Invitae?utm_source=openai)) Operationally, Invitae focused on a broad menu of medical genetics services. Its core offering included hereditary cancer testing, reproductive health testing, pediatric genetics, neurology, and rare-disease panels, along with interpretation and reporting tools designed to support clinical decision-making. The company’s strategy was to expand the number of genes and disease areas covered by its tests, and its 2016 panel expansion showed a deliberate push to deepen clinical utility across a wider set of indications. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/2016/default.aspx?utm_source=openai)) From a competitive standpoint, Invitae positioned itself as a scaled specialist in the genetic testing market, competing with other genomics-focused diagnostics companies and diversified clinical laboratories. Its value proposition was built on breadth of assay coverage, a digitally enabled testing workflow, and an ambition to become a more comprehensive platform for medical genetics. In 2020, the company announced a planned combination with ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology, underlining how central oncology and precision medicine were to its strategic narrative. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/press-release-details/2020/Invitae-and-ArcherDX-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology/default.aspx?utm_source=openai)) The most important recent development for investors is the company’s sharp operational reset. After significant financial stress, Invitae sold assets in 2024, and Labcorp completed the acquisition of select Invitae assets on August 5, 2024. As a result, the name “NVTA” should now be viewed through the lens of restructuring, asset sales, and a much smaller footprint than the one Invitae had during its growth phase. For investors in French-speaking markets, this is no longer a straightforward growth stock story; it is a U.S. healthcare situation marked by restructuring and asset monetization. The company was a U.S. issuer with exposure to the NYSE/NASDAQ universe, but its economic profile has materially changed. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/press-release-details/2024/Labcorp-Finalizes-Acquisition-of-Select-Assets-of-Invitae-2024-x_frzgmkDn/default.aspx?utm_source=openai)) In short, Invitae became a recognizable name in U.S. medical genetics through hereditary cancer and molecular diagnostic testing, but recent divestitures have transformed it from a broad-based genomics growth company into a much more complex, event-driven equity case. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/press-release-details/2024/Labcorp-Finalizes-Acquisition-of-Select-Assets-of-Invitae-2024-x_frzgmkDn/default.aspx?utm_source=openai))